994 related articles for article (PubMed ID: 30449221)
1. A patent review of the ubiquitin ligase system: 2015-2018.
Li X; Elmira E; Rohondia S; Wang J; Liu J; Dou QP
Expert Opin Ther Pat; 2018 Dec; 28(12):919-937. PubMed ID: 30449221
[TBL] [Abstract][Full Text] [Related]
2. Targeting E3 ubiquitin ligases for cancer therapy.
Sun Y
Cancer Biol Ther; 2003; 2(6):623-9. PubMed ID: 14688465
[TBL] [Abstract][Full Text] [Related]
3. Novel strategies to target the ubiquitin proteasome system in multiple myeloma.
Lub S; Maes K; Menu E; De Bruyne E; Vanderkerken K; Van Valckenborgh E
Oncotarget; 2016 Feb; 7(6):6521-37. PubMed ID: 26695547
[TBL] [Abstract][Full Text] [Related]
4. Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities.
Landré V; Rotblat B; Melino S; Bernassola F; Melino G
Oncotarget; 2014 Sep; 5(18):7988-8013. PubMed ID: 25237759
[TBL] [Abstract][Full Text] [Related]
5. E2-E3 ubiquitin enzyme pairing - partnership in provoking or mitigating cancers.
Chang SC; Zhang BX; Ding JL
Biochim Biophys Acta Rev Cancer; 2022 Mar; 1877(2):188679. PubMed ID: 35074437
[TBL] [Abstract][Full Text] [Related]
6. Cullin-RING Ligases as attractive anti-cancer targets.
Zhao Y; Sun Y
Curr Pharm Des; 2013; 19(18):3215-25. PubMed ID: 23151137
[TBL] [Abstract][Full Text] [Related]
7. Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer.
Soucy TA; Smith PG; Rolfe M
Clin Cancer Res; 2009 Jun; 15(12):3912-6. PubMed ID: 19509147
[TBL] [Abstract][Full Text] [Related]
8. Identification and Characterization of Physiological Pairing of E2 Ubiquitin-Conjugating Enzymes and E3 Ubiquitin Ligases.
Brillada C; Trujillo M
Methods Mol Biol; 2023; 2581():13-29. PubMed ID: 36413307
[TBL] [Abstract][Full Text] [Related]
9. Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from rational design, nature and old drug reposition.
Patel K; Ahmed ZS; Huang X; Yang Q; Ekinci E; Neslund-Dudas CM; Mitra B; Elnady FA; Ahn YH; Yang H; Liu J; Dou QP
Future Med Chem; 2018 Sep; 10(17):2087-2108. PubMed ID: 30066579
[TBL] [Abstract][Full Text] [Related]
10. Ubiquitination and deubiquitination: Implications on cancer therapy.
Dagar G; Kumar R; Yadav KK; Singh M; Pandita TK
Biochim Biophys Acta Gene Regul Mech; 2023 Dec; 1866(4):194979. PubMed ID: 37633647
[TBL] [Abstract][Full Text] [Related]
11. Targeting the ubiquitin pathway for cancer treatment.
Liu J; Shaik S; Dai X; Wu Q; Zhou X; Wang Z; Wei W
Biochim Biophys Acta; 2015 Jan; 1855(1):50-60. PubMed ID: 25481052
[TBL] [Abstract][Full Text] [Related]
12. Dual-color pulse-chase ubiquitination assays to simultaneously monitor substrate priming and extension.
Scott DC; Schulman BA
Methods Enzymol; 2019; 618():29-48. PubMed ID: 30850057
[TBL] [Abstract][Full Text] [Related]
13. [The role of different E3 ubiquitin ligases in regulation of the P53 tumor suppressor protein].
Daks AA; Melino D; Barlev NA
Tsitologiia; 2013; 55(10):673-87. PubMed ID: 25509121
[TBL] [Abstract][Full Text] [Related]
14. A High-Throughput Screening Strategy for Development of RNF8-Ubc13 Protein-Protein Interaction Inhibitors.
Weber E; Rothenaigner I; Brandner S; Hadian K; Schorpp K
SLAS Discov; 2017 Mar; 22(3):316-323. PubMed ID: 27909234
[TBL] [Abstract][Full Text] [Related]
15. Hidden targets of ubiquitin proteasome system: To prevent diabetic nephropathy.
Goru SK; Kadakol A; Gaikwad AB
Pharmacol Res; 2017 Jun; 120():170-179. PubMed ID: 28363724
[TBL] [Abstract][Full Text] [Related]
16. From Discovery to Bedside: Targeting the Ubiquitin System.
Wertz IE; Wang X
Cell Chem Biol; 2019 Feb; 26(2):156-177. PubMed ID: 30554913
[TBL] [Abstract][Full Text] [Related]
17. The significance of ubiquitin proteasome pathway in cancer development.
Yerlikaya A; Yöntem M
Recent Pat Anticancer Drug Discov; 2013 Sep; 8(3):298-309. PubMed ID: 23061719
[TBL] [Abstract][Full Text] [Related]
18. The ubiquitin-proteasome pathway an emerging anticancer strategy for therapeutics: a patent analysis.
Jain CK; Arora S; Khanna A; Gupta M; Wadhwa G; Sharma SK
Recent Pat Anticancer Drug Discov; 2015; 10(2):201-13. PubMed ID: 25877716
[TBL] [Abstract][Full Text] [Related]
19. Classification and interaction modes of 40 rice E2 ubiquitin-conjugating enzymes with 17 rice ARM-U-box E3 ubiquitin ligases.
Bae H; Kim WT
Biochem Biophys Res Commun; 2014 Feb; 444(4):575-80. PubMed ID: 24486490
[TBL] [Abstract][Full Text] [Related]
20. Strategies for the identification of ubiquitin ligase inhibitors.
Goldenberg SJ; Marblestone JG; Mattern MR; Nicholson B
Biochem Soc Trans; 2010 Feb; 38(Pt 1):132-6. PubMed ID: 20074047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
